ATAK™ Development Timeline

Over 120 years of research has resulted in the emergence of Myeloid Therapeutics & its platform technologies

1882

Wikapedia_icon_lo.png

Élie Metchnikof discovers Phagocytes (myeloid cells)

His theory, that certain white blood cells (myeloid cells) could engulf and destroy harmful bodies such as bacteria, met with scepticism from leading specialists including Louis Pasteur, Behring and others. At the time, most bacteriologists believed that white blood cells ingested pathogens and then spread them further through the body. His major supporter was Rudolf Virchow, who published his research in his Archiv für pathologische Anatomie und Physiologie und für klinische Medizin (now called the Virchows Archiv).[12] His discovery of these phagocytes ultimately won him the Nobel Prize in 1908

1902

Wikapedia_icon_lo.png

Almroth Wright

Almroth Wright subsequently emphasized the importance of phagocytes (polymorphonuclear leukocytes, initially described as microphages) and of plasma/ serum-dependent opsonisation (from the Greek, to prepare for eating) in resistance to infection.

Wikapedia_icon_lo.png

1968

Ralph van Furth & Zanvill Cohn

Ralph van Furth & Zanvill Cohn describe a  group of leukocytes that shared phenotypic features (e.g., a single nucleus) and biological functions (e.g., phagocytosis). In spite of the subsequent improved characterisation of diverse cells arising from common progenitors and sharing differentiation antigen markers, there is still considerable confusion in categorising myeloid cell sub-populations

1976

Wikapedia_icon_lo.png

Siamon Gordon

Siamon Gordon  identified the pan-macrophage marker F4/80. Subsequent studies led to the identification of various scavenger receptors and the cloning of the pattern recognition receptor, Dectin-1 

1983

Wikapedia_icon_lo.png

Alberto Motavani

Alberto Motavani is the first identify monocyte chemoattractant protein (CCL2) as a primary chemokine for recruiting myeloid cells. [PUT IN MORE TRAFFICKING INFO HERE]

1989

Wikapedia_icon_lo.png

Charles Janeway

Janeway predicted in 1989 that activation of the adaptive immune response is controlled by the more ancient innate immune system. He proposed a general theory of innate immune recognition (pattern recognition theory) and suggested the principles of innate control of adaptive immunity.[4] These predictions have been confirmed in subsequent years and now form the conceptual framework for the current understanding of the innate immune system and the links between innate and adaptive immunity.[5]

Myeloid Tx

Preclinical

Single arm open-label clinical trial of MT-101 in subjects with advanced CD5+ expressing T cell lymphoma malignancies

Phase Ia: MT-101

Phase 1 programs planned

Phase Ib: MT-102

Single arm open-label clinical trial of MT-102 in subjects with advanced HER2+ expressing gatric/GEJ malignancies

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139